100th patient joins ChariotMS trial for multiple sclerosis
The trial is testing whether Mavenclad could benefit upper limb movement in MS patients
Read More
Tag: Mavenclad
Multiple sclerosis trial focusing on people who can’t walk begins recruitment
Trial will evaluate whether Mavenclad can slow the rate of upper limb disability progression
Read More
FDA green light for Merck’s Mavenclad
The drug is the first oral MS treatment to provide two years of proven efficacy with a maximum of 20 days of treatment.
Read More
Scotland endorses five new therapies for NHS use
Five new medicines are to be funded by the NHS in Scotland, bringing new treatment options for cancer, multiple sclerosis and rheumatoid arthritis, as well as a new contraceptive.
Read More
NICE backs Merck’s Mavenclad for MS
Merck’s Mavenclad is being backed by the National Institute for Health and Clinical Excellence as an option for treating highly active multiple sclerosis in adults on the NHS.
Read More
New analysis backs benefit-risk profile of Merck’s Mavenclad
Merck has released new data showing a positive benefit-risk profile for its multiple sclerosis drug Mavenclad.
Read More
Merck’s MS pill Mavenclad launched in the UK and Ireland
Merck’s Mavenclad is now available in the UK and Ireland to treat highly active relapsing multiple sclerosis in adults.
Read More
EU nod for Merck’s MS therapy Mavenclad
Merck’s Mavenclad has bagged approval in the European Union, Norway, Liechtenstein and Iceland to treat highly active relapsing multiple sclerosis.
Read More
EMA advisors back eight medicines for approval
Eight medicines have been backed for approval by the European Medicines Agency’s Committee for Medicinal Products for Human Use, including new therapies to treat hepatitis C, multiple sclerosis and cancer.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
